NEW YORK (Reuters Health) - Some patients with metastatic clear-cell renal cancer appear to fare relatively well when treated with sunitinib before undergoing planned nephrectomy -- even though progression rates are high when sunitinib is suspended during the surgical period, according to a new study reported in European Urology online May 17.
For more information, please visit: http://www.thedoctorschannel.com/video/4463.html
Link to this comment:
All Comments (0)